State of the Science Summit on Hematologic Malignancies

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Jane N. Winter, MD, discusses immunotherapy in the treatment of patients with Hodgkin lymphoma.

Jayesh Mehta, MD, discusses combination therapies in multiple myeloma, as well as the continued importance of stem cell transplant.

Ashley Rosko, MD, assistant professor in the Division of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment for elderly patients with multiple myeloma.

Alice Mims, MD, provides updates on the field of myeloproliferative neoplasms, with a focus on myelofibrosis.

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Jerry W. Mitchell, MD, oncologist, Zangmeister Cancer Center, discusses clinical trials exploring medical marijuana for patients with cancer.

Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Reem Karmali, MD, discusses ongoing key trials of CAR T-cell therapy, the chronic safety concerns with the treatment, and what combinations have the most potential.

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the concerns of chimeric antigen receptor (CAR) T-cell therapy.

Narendranath Epperla, MD, discusses the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.

Ashley Rosko, MD, discusses available therapies, others under investigation, and supportive care methods being utilized for patients with multiple myeloma.

Jonathan Brammer, MD, discusses exciting therapeutic developments for patients with T-cell lymphoma.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia.

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Ellen K. Ritchie, MD, highlights current and emerging novel treatments, and the possibility of using immunotherapy to treat patients with systemic mastocytosis, advanced symptomatic hypereosinoophic disorder, myelofibrosis, and chronic myelomonocytic leukemia

John P. Leonard, MD, discusses advancements across hematologic malignancies and pivotal trial data he is anticipating at the 2017 ASCO Annual Meeting.

Sarah Rutherford, MD, John P. Leonard, M.D./Gwirtzman Family Research Scholar in Lymphoma , assistant professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification and prevalence of double-hit and double-expressor lymphomas.

Gail J. Roboz, MD, discusses the recent FDA approval of midostaurin and what else is emerging in the treatment landscape in AML.

Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.

Ruben Niesvizky, MD, discusses some of the exciting advances, the potential of chimeric antigen receptor T-cell therapy, and emerging combination regimens on the horizon in multiple myeloma.

Jia Ruan, MD, PhD, associate professor of Clinical Medicine, Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification of T-cell lymphomas.

Tsiporah B. Shore, MD, associate director of the Blood and Bone Marrow Transplant Program of Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses stem cell transplantation in patients with hematologic malignancies and are of ethnic populations.